Сравнение
DSIP vs. Bremelanotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
62568-57-4
189691-06-3
Молекулярная масса
848.81 g/mol
1025.18 g/mol
Период полувыведения
0.1 h
2.7 h
Последовательность
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHМеханизм действия
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
4
5
из них на людях
1
5
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between DSIP and Bremelanotide?
- DSIP is classified as "Исследования (прочее)", while Bremelanotide is classified as "Исследования (прочее)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Bremelanotide?
- The highest available evidence level is "Исследование на людях" for DSIP and "РКИ на людях" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Bremelanotide in Germany and the United States?
- Германия: DSIP — Не одобрено, Bremelanotide — Не одобрено. США: DSIP — Не одобрено, Bremelanotide — Рецептурный. These are factual summaries with source and review date on the individual pages.